An­timi­cro­bial re­sis­tance biotech se­cures $37M with ex-Cure­Vac CEO Franz-Wern­er Haas at the helm

Three months in­to his role at the helm of GSK’s bac­te­r­i­al in­fec­tion spin­out Lim­maT­e­ch, Cure­Vac vet­er­an Franz-Wern­er Haas is fo­cused on scal­ing the com­pa­ny. And …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER